Bone marrow transplantation—The Marsden experience

Summary In a single centre, 52 newly diagnosed patients with acute myeloid leukaemia (AML) under the age of 56 years received induction chemotherapy commencing with high-dose cytosine arabinoside (Ara-C) and etoposide (Protocol BFI 1), followed by Ara-C, 6 thioguanine (6TG). A total of 67% of patients entered remission using these drugs. An anthracycline was added for those patients not in remission. The overall remission rate (CR) was 86.5% (45/52), with a minimum follow-up of 90 days. Patients are hospitalised for relatively short periods, and consequently require less blood product and antibiotic support. Patients in continuing first remission following, induction with Ara-C and etoposide are similar in number to those in continuing first remission who initially received an anthracycline. This would imply that the efficiency of Ara-C and etoposide in inducing long-term disease-free survival is comparable with anthracycline-containing regimens. We conclude that high-dose Ara-C and etoposide used in the first induction cycle for treating AML have good antileukaemic effect with acceptable toxicity.Patients with AML with first remission can now expect a cure rate of 45-60% following either ABMT or BMT (Hurd, 1987). These results, however, depend upon obtaining remission, higher CR rates rendering more

show abstract

High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study

Parikh

Powles²,

Treleaven³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Bone marrow transplantation—The Marsden experience

Cited by 1 publication

References 12 publications

High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study

High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study

Contact Info

Product

Resources

About